Mckesson earnings release, May 7, 2026

Mckesson Corp (MCK) · Form 8-K, Item 2.02 · Filed · SEC filing

McKESSON REPORTS FISCAL 2026 FOURTH QUARTER AND FULL YEAR RESULTS, PROVIDES FISCAL 2027 GUIDANCE,

AND REAFFIRMS LONG-TERM FINANCIAL GROWTH TARGETS

IRVING, Texas, May 7, 2026 -

McKesson Corporation (NYSE:MCK) today announced results for the fourth quarter and fiscal year ended March 31, 2026.

Fourth Quarter Highlights:

• Consolidated revenues of $96.3 billion increased 6%.

• Earnings per diluted share of $13.71 increased $3.70.

• Adjusted Earnings per Diluted Share of $11.69 increased 16%.

• McKesson entered into a $2.25 billion accelerated share repurchase program.

• McKesson's Board of Directors approved a $5.0 billion increase to the share repurchase program, bringing the total share repurchase authorization to $7.7 billion as of April 2026.

Full Year Highlights:

• Consolidated revenues of $403.4 billion increased 12%.

• Earnings per diluted share of $38.38 increased $12.66.

• Adjusted Earnings per Diluted Share of $39.11 increased 18%, above previously communicated long-range growth targets.

• Cash flow from operations of $6.2 billion and Free Cash Flow of $5.4 billion.

Outlook:

• Establishing fiscal 2027 Adjusted Earnings per Diluted Share guidance range of $43.80 to $44.60, which indicates 12% to 14% forecasted growth compared to the prior year.

• Reaffirming long-term Adjusted Earnings per Diluted Share growth target of 13% to 16%.

• The Company does not forecast GAAP earnings per diluted share¹.

"McKesson's fourth quarter results reflect the strength of our diversified portfolio and disciplined execution against our strategic priorities. Our Fiscal 2026 performance, headlined by 12% revenue growth and 18% adjusted EPS growth, exceeded our long-range growth targets and demonstrates our ability to consistently deliver growth and operating leverage across the enterprise," said Brian Tyler, chief executive officer. "We delivered significant progress - expanding specialty provider support, accelerating patient access through our scaled and integrated biopharma support services, and continuing to optimize our portfolio through the divestiture of Europe and the planned separation of our Medical-Surgical business. These accomplishments are a direct result of the talent and operational excellence of our employees, and I want to thank Team McKesson for their continued dedication throughout the year."

"Looking ahead to fiscal 2027, we are well-positioned to build upon this momentum," said Mr. Tyler. "We remain committed to executing with discipline across the portfolio, investing in high-growth and high-margin areas in Oncology and Biopharma Services. By combining our operating execution with a more focused and optimized portfolio, we will continue to deliver sustainable growth and create long-term value for our shareholders."¹

See below under "Fiscal 2027 Outlook" for full explanation

Fiscal 2026 Fourth Quarter and Full Year Result Summary

Fourth quarter revenues were $96.3 billion, an increase of 6% from a year ago, driven by growth in the distribution of oncology and multispecialty products, including contributions from acquisitions in the Oncology & Multispecialty segment, and growth in the North American Pharmaceutical segment due to increased prescription volumes, partially offset by lower contributions from branded pharmaceuticals.

Fourth quarter earnings per diluted share was $13.71 compared to $10.01 a year ago, an increase of $3.70. Full year earnings per diluted share was $38.38 compared to $25.72 a year ago, an increase of $12.66.

Fourth quarter Adjusted Earnings per Diluted Share was $11.69 compared to $10.12 a year ago, an increase of 16%, driven by strong operational growth, including contributions from acquisitions in the Oncology & Multispecialty segment, a lower share count, and a lower tax rate. Full year Adjusted Earnings per Diluted Share was $39.11 compared to $33.05 a year ago, an increase of 18%, driven by strong operational growth across the business and a lower share count.

During the three months ended March 31, 2026, McKesson generated cash flow from operations of $3.4 billion, and invested $185 million in capital expenditures, resulting in Free Cash Flow of $3.2 billion. During the fiscal year, McKesson generated cash from operations of $6.2 billion, and invested $745 million in capital expenditures, resulting in Free Cash Flow of $5.4 billion.

For the full year, McKesson returned $5.1 billion of cash to shareholders, which included $4.8 billion of common stock repurchases and $381 million of dividend payments.

Business Highlights

• McKesson announced Donald R. Knauss will complete his service on the Board of Directors at the 2026 Annual Stockholders meeting, in accordance with the company's governance policy. Effective May 1, 2026, the Board elected Brian Tyler as Chair of the Board, and Dominic J. Caruso as Lead Independent Director.

• McKesson remains committed to a disciplined capital allocation framework, prioritizing investments in high-margin growth areas while returning excess capital to shareholders through our robust share repurchase program.

◦ The Board of Directors approved an additional $5.0 billion share repurchase authorization of the company's common shares, bringing total authorized repurchases to $7.7 billion as of April 2026.

◦ During the fourth quarter, McKesson entered into a $2.25 billion accelerated share repurchase program. In the quarter, McKesson completed $2.7 billion share repurchases, including $2.25 billion under the accelerated share repurchase program.

• In April 2026, The US Oncology Network expanded its footprint with the addition of Cancer Care Northwest, strengthening its position in community oncology practices.

• Effective May 1, 2026, PRISM Vision Group grew its network by welcoming the Retina Macula Institute located in Southern California further aligning with ophthalmology practices nationwide.

• ... (truncated)minority ownership interest in the Medical-Surgical Solution segment, subject to regulatory approvals and customary closing conditions.

• In April 2026, McKesson completed initial financing transactions in support of the planned separation of Medical-Surgical Solutions segment, including a secured $1.0 billion term loan and $1.0 billion revolving credit facility.

• On January 30, 2026, McKesson closed the transaction to sell its retail and distribution businesses in Norway, representing the final phase to fully exit its European operations.

North American Pharmaceutical Segment

Fourth Quarter

• Revenues were $79.1 billion, an increase of 3%, driven by increased prescription transaction volumes, including higher volumes from specialty products, partially offset by lower contributions from branded pharmaceuticals.

• Segment Operating Profit was $1.2 billion. Adjusted Segment Operating Profit was $980 million, an increase of 11%, driven by growth in the distribution of specialty products to health systems.

Full Year

• Revenues were $336.7 billion, an increase of 11%, driven by increased prescription transaction volumes, including higher volumes from retail national account customers and specialty products.

• Segment Operating Profit was $3.7 billion. Adjusted Segment Operating Profit was $3.5 billion, an increase of 10%, driven by growth in the distribution of specialty products.

Oncology & Multispecialty Segment

Fourth Quarter

• Revenues were $12.7 billion, an increase of 35%, driven by growth in provider solutions and specialty distribution, including contributions from acquisitions.

• Segment Operating Profit was $301 million. Adjusted Segment Operating Profit was $385 million, an increase of 53%, driven by growth in provider solutions and specialty distribution, including contributions from acquisitions.

Full Year

• Revenues were $48.4 billion, an increase of 31%, driven by growth in provider solutions and specialty distribution, including contributions from acquisitions.

• Segment Operating Profit was $1.1 billion. Adjusted Segment Operating Profit was $1.4 billion, an increase of 53%, driven by growth in provider solutions and specialty distribution, including contributions from acquisitions.

Prescription Technology Solutions Segment

Fourth Quarter

• Revenues were $1.5 billion, an increase of 12%, driven by increased prescription volumes in the third-party logistics and technology services businesses.

• Segment Operating Profit was $286 million. Adjusted Segment Operating Profit was $322 million, an increase of 13%, driven by higher demand for access solutions.

Full Year

• Revenues were $5.8 billion, an increase of 11%, driven by increased prescription volumes in the third-party logistics and technology services businesses.

• Segment Operating Profit was $1.0 billion. Adjusted Segment Operating Profit was $1.1 billion, an increase of 17%, driven by higher demand for access solutions.

Medical-Surgical Solutions Segment

Fourth Quarter

• Revenues were $2.9 billion, an increase of 1%, driven by specialty pharmaceutical volumes, offset by lower contributions from the ambulatory care channel.

• Segment Operating Profit was $232 million. Adjusted Segment Operating Profit was $271 million, a decrease of 5%, driven by lower contributions from the ambulatory care channel.

Full Year

• Revenues were $11.5 billion, an increase of 1%, driven by specialty pharmaceutical volumes, offset by lower contributions from the ambulatory care channel.

• Segment Operating Profit was $938 million. Adjusted Segment Operating Profit was $1.0 billion, an increase of 1%, driven by cost optimization, offset by lower contributions from the ambulatory care channel.

Fiscal 2027 Outlook

McKesson does not provide forward-looking guidance on a GAAP basis as the company is unable to provide a quantitative reconciliation of forward-looking Non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort. McKesson cannot reasonably forecast LIFO inventory-related adjustments, certain litigation loss and gain contingencies, transaction related expenses and adjustments, restructuring, impairment and related charges, and other adjustments, which are difficult to predict and estimate. These items are generally uncertain and depend on various factors, many of which are beyond the company's control, and as such, any associated estimate and its impact on GAAP performance could vary materially.

McKesson is establishing Fiscal 2027 Adjusted Earnings per Diluted Share guidance to $43.80 to $44.60.

Long-Term Growth Targets

McKesson continues to strengthen its portfolio of differentiated assets and capabilities, advancing health outcomes while driving sustainable value creation. The Company is reaffirming long-term Adjusted Earnings per Diluted Share growth targets of 13% to 16% as well as its long-term Adjusted Segment Operating Profit growth targets as follows:

• North American Pharmaceutical of 5% to 8%

• Oncology & Multispecialty of 13% to 16%

• Prescription Technology Solutions of 10% to 13%

Additional modeling considerations will be provided in the earnings call presentation.

Conference Call Details

McKesson has scheduled a conference call for today, Thursday, May 7, 2026, at 4:30 PM ET to discuss the company’s financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website at investor.mckesson.com.

Upcoming Investor Event

McKesson management will be participating in the BofA Securities 2026 Healthcare Conference on May 12, 2026.

The audio webcasts, and a complete listing of upcoming events for the investment community, including details and updates, will be available on McKesson's Investor Relations website.

Non-GAAP Financial Measures... (truncated)Gross Profit, Adjusted Operating Expenses, Adjusted Other Income, Adjusted Interest Expense, Adjusted Income Tax Expense,

Adjusted Earnings, Adjusted Earnings per Diluted Share, Adjusted Segment Operating Profit, Adjusted Segment Operating Profit Margin, Adjusted Corporate Expenses, Adjusted Operating Profit, and Free Cash Flow which are financial measures not calculated in accordance with GAAP. Refer to the “Supplemental Non-GAAP Financial Information” section of the accompanying financial statement tables for the definitions and usefulness of the company’s Non-GAAP financial measures and the attached schedules for reconciliations of the differences between the Non-GAAP financial measures and their most directly comparable GAAP financial measures.

Cautionary Statements

Financial statements

Income Statement

Fourth Quarter — Fiscal 2026 Fourth Quarter and Full Year Result Summary ($ in millions, except per share amounts)

Fourth Quarter – FY26Fourth Quarter – FY25Fourth Quarter – ChangeFull Year – FY26Full Year – FY25Full Year – Change
Revenues96,29590,8236403,430359,05112
Net income attributable to McKesson Corporation1,6821,260334,7623,29545
Adjusted Earnings21,4341,274134,8534,23415
Earnings per diluted common share attributable to McKesson Corporation13.7110.013738.3825.7249
Adjusted Earnings per Diluted Share211.6910.121639.1133.0518

Income Statement

Three Months Ended March 31, — (in millions, except per share amounts)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025ChangeYear Ended March 31, – 2026Year Ended March 31, – 2025Change
Revenues96,29590,8236403,430359,05112
Cost of sales-92,251-87,1846-388,880-345,72812
Gross profit4,0443,6391114,55013,3239
Selling, distribution, general, and administrative expenses-1,796-1,975-9-8,096-8,507-5
Claims and litigation charges, net13-108-103
Restructuring, impairment, and related charges, net-99-7336-245-286-14
Total operating expenses-1,894-2,048-8-8,338-8,901-6
Operating income2,1501,591356,2124,42240
Other income (expense), net36-3121623620217
Interest expense-61-4536-247-265-7
Income before income taxes2,1251,515406,2014,35942
Income tax expense-270-20929-1,102-87826
Net income1,8551,306425,0993,48146
Net income attributable to noncontrolling interests-173-46276-337-18681
Net income attributable to McKesson Corporation1,6821,260334,7623,29545
Earnings per common share attributable to McKesson Corporation (a)Diluted13.7110.013738.3825.7249
Earnings per common share attributable to McKesson Corporation (a)Basic13.7810.063738.5525.8649
Earnings per common share attributable to McKesson Corporation (a)Dividends declared per common share0.820.71153.172.7515
Weighted-average common shares outstandingDiluted122.7125.9-3124.1128.1-3
Weighted-average common shares outstandingBasic122.1125.2-2123.6127.4-3

Income Statement

Three Months Ended March 31, — (in millions)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025ChangeYear Ended March 31, – 2026Year Ended March 31, – 2025Change
Gross profit (GAAP)4,0443,6391114,55013,3239
Pre-tax adjustments:LIFO inventory-related adjustments-182-3-21082-356
Pre-tax adjustments:Gains from antitrust legal settlements-260-100-23-444-95
Pre-tax adjustments:Restructuring, impairment, and related charges, net-5-10058-100
Pre-tax adjustments:Other adjustments, net17-100517-71
Pre-tax adjustments:Adjusted Gross Profit (Non-GAAP)3,8623,3881414,32213,03610
Pre-tax adjustments:Total operating expenses (GAAP)-1,894-2,048-8-8,338-8,901-6
Pre-tax adjustments:Amortization of acquisition-related intangibles73504627622622
Pre-tax adjustments:Transaction-related expenses and adjustments (1) (2) (3) (4)-41244-268741-136
Pre-tax adjustments:Restructuring, impairment, and related charges, net (6)997336245286-14
Pre-tax adjustments:Claims and litigation charges, net (7)-1-3108-103
Pre-tax adjustments:Other adjustments, net (8)-6-450-5-209-98
Pre-tax adjustments:Adjusted Operating Expenses (Non-GAAP)-2,141-1,88514-8,093-7,7494
Pre-tax adjustments:Other income (loss), net (GAAP)36-3121623620217
Pre-tax adjustments:Transaction-related expenses and adjustments-1-100
Pre-tax adjustments:Other adjustments, net (9) (10)87-100130-100
Pre-tax adjustments:Adjusted Other Income (Non-GAAP)3656-36236331-29
Pre-tax adjustments:Interest expense (GAAP)-61-4536-247-265-7
Pre-tax adjustments:Transaction-related expenses and adjustments25-601721-19
Pre-tax adjustments:Adjusted Interest Expense (Non-GAAP)-59-4048-230-244-6
Pre-tax adjustments:Income tax expense (GAAP)-270-20929-1,102-87826
Tax adjustments:Amortization of acquisition-related intangibles-18-1250-66-5520
Tax adjustments:Transaction-related expenses and adjustments (1) (2) (3) (4)59-883831-16294
Tax adjustments:LIFO inventory-related adjustments4855-22350
Tax adjustments:Gains from antitrust legal settlements67-1006115-95
Tax adjustments:Restructuring, impairment, and related charges, net (6)-26-1844-64-90-29
Tax adjustments:Claims and litigation charges, net (7)-28-100
Tax adjustments:Other adjustments, net (8) (9) (10)1-1710626-100
Tax adjustments:Adjusted Income Tax Expense (Non-GAAP)-206-1975-1,140-94820

Income Statement

Year Ended March 31, — (in millions)

Year Ended March 31, – 2026 – As reported (GAAP)Year Ended March 31, – 2026 – AdjustmentsYear Ended March 31, – 2026 – As adjusted (Non-GAAP)Year Ended March 31, – 2025 – As reported (GAAP)Year Ended March 31, – 2025 – AdjustmentsYear Ended March 31, – 2025 – As adjusted (Non-GAAP)As reported (GAAP)As adjusted (Non-GAAP)
REVENUESNorth American Pharmaceutical336,652336,652304,507304,5071111
REVENUESOncology & Multispecialty48,42348,42336,86236,8623131
REVENUESPrescription Technology Solutions5,8055,8055,2165,2161111
REVENUESMedical-Surgical Solutions11,50711,50711,38011,38011
REVENUESOther1,0431,0431,0861,086-4-4
REVENUESRevenues403,430403,430359,051359,0511212
OPERATING PROFITNorth American Pharmaceutical (2) (6) (7) (8)3,658-2063,4522,9452003,1452410
OPERATING PROFITOncology & Multispecialty (4) (9)1,1492861,4357671699365053
OPERATING PROFITPrescription Technology Solutions (6)1,044851,129875869611917
OPERATING PROFITMedical-Surgical Solutions (3) (6)938911,0297792431,022201
OPERATING PROFITOther (1)590-5167454-64899354
OPERATING PROFITSubtotal7,379-2607,1195,4206926,1123616
OPERATING PROFITCorporate expenses, net (1) (2) (3) (6) (7) (10) (11)-931277-654-796302-4941732
OPERATING PROFITIncome before interest expense and income taxes6,448176,4654,6249945,6183915
OPERATING PROFIT AS A % OF REVENUESNorth American Pharmaceutical1.091.030.971.0312
OPERATING PROFIT AS A % OF REVENUESOncology & Multispecialty2.372.962.082.542942
OPERATING PROFIT AS A % OF REVENUESPrescription Technology Solutions17.9819.4516.7818.42120103
OPERATING PROFIT AS A % OF REVENUESMedical-Surgical Solutions8.158.946.858.98130-4
OPERATING PROFIT AS A % OF REVENUESOther56.577.094.974.42267

Balance Sheet

March 31, 2026 — (in millions, except per share amounts)

March 31, 2026 – ASSETSMarch 31, 2025 – ASSETS
Current assetsCash and cash equivalents3,9755,691
Current assetsReceivables, net27,98525,643
Current assetsInventories, net24,20723,001
Current assetsPrepaid expenses and other1,0431,063
Current assetsTotal current assets57,21055,398
Current assetsProperty, plant, and equipment, net2,6682,502
Current assetsOperating lease right-of-use assets2,0581,782
Current assetsGoodwill11,31610,022
Current assetsIntangible assets, net4,0791,464
Current assetsOther non-current assets4,9923,972
Current assetsTotal assets82,32375,140
Current liabilitiesDrafts and accounts payable59,97355,330
Current liabilitiesCurrent portion of long-term debt1,2671,191
Current liabilitiesCurrent portion of operating lease liabilities287258
Current liabilitiesOther accrued liabilities5,4904,825
Current liabilitiesTotal current liabilities67,01761,604
Current liabilitiesLong-term debt5,2594,463
Current liabilitiesLong-term deferred tax liabilities1,3301,029
Current liabilitiesLong-term operating lease liabilities1,8011,478
Current liabilitiesLong-term litigation liabilities5,0915,601
Current liabilitiesOther non-current liabilities2,6592,659
Current liabilitiesRedeemable noncontrolling interests943
McKesson Corporation stockholders’ deficitCommon stock, $0.01 par value, 800 shares authorized, 280 and 279 shares issued at March 31, 2026 and March 31, 2025, respectively33
McKesson Corporation stockholders’ deficitAdditional paid-in capital8,2848,373
McKesson Corporation stockholders’ deficitRetained earnings22,29117,921
McKesson Corporation stockholders’ deficitAccumulated other comprehensive loss-745-932

Cash Flow

Year Ended March 31, — (in millions)

Year Ended March 31, – 2026Year Ended March 31, – 2025
OPERATING ACTIVITIESNet income5,0993,481
Adjustments to reconcile to net cash used in operating activities:Depreciation256242
Adjustments to reconcile to net cash used in operating activities:Amortization473394
Adjustments to reconcile to net cash used in operating activities:Asset impairment charges5598
Adjustments to reconcile to net cash used in operating activities:Deferred taxes230-110
Adjustments to reconcile to net cash used in operating activities:Charges (credits) associated with last-in, first-out inventory method-21082
Adjustments to reconcile to net cash used in operating activities:Non-cash operating lease expense261245
Adjustments to reconcile to net cash used in operating activities:Loss (gain) from sales of businesses and investments-573485
Adjustments to reconcile to net cash used in operating activities:Provision for bad debts100-130
Adjustments to reconcile to net cash used in operating activities:Other non-cash items302424
Changes in assets and liabilities:Receivables-1,999-3,935
Changes in assets and liabilities:Inventories-1,082-2,270
Changes in assets and liabilities:Drafts and accounts payable4,3178,301
Changes in assets and liabilities:Operating lease liabilities-270-404
Changes in assets and liabilities:Taxes-339-136
Changes in assets and liabilities:Litigation liabilities-684-401
Changes in assets and liabilities:Other219-281
Changes in assets and liabilities:Net cash provided by operating activities6,1556,085
INVESTING ACTIVITIESPayments for property, plant, and equipment-436-537
INVESTING ACTIVITIESCapitalized software expenditures-309-322
INVESTING ACTIVITIESAcquisitions, net of cash, cash equivalents, and restricted cash acquired-3,416-24
INVESTING ACTIVITIESProceeds from sales of businesses and investments, net830179
INVESTING ACTIVITIESOther-101-29
INVESTING ACTIVITIESNet cash used in investing activities-3,432-733
FINANCING ACTIVITIESProceeds from short-term borrowings9,24715,086
FINANCING ACTIVITIESRepayments of short-term borrowings-9,247-15,086
FINANCING ACTIVITIESProceeds from issuances of long-term debt1,990498
FINANCING ACTIVITIESRepayments of long-term debt-1,207-519
Common stock transactions:Issuances89101
Common stock transactions:Share repurchases-4,750-3,146
Common stock transactions:Dividends paid-381-345
Common stock transactions:Other-372-554
Common stock transactions:Net cash used in financing activities-4,631-3,965
Common stock transactions:Effect of exchange rate changes on cash, cash equivalents, and restricted cash20-16
Common stock transactions:Net increase (decrease) in cash, cash equivalents, and restricted cash-1,8881,371
Common stock transactions:Cash, cash equivalents, and restricted cash at beginning of period5,9564,585
Common stock transactions:Cash, cash equivalents, and restricted cash at end of period4,0685,956
Common stock transactions:Less: Restricted cash at end of period included in Prepaid expenses and other-93-265
Common stock transactions:Cash and cash equivalents at end of period3,9755,691

Cash Flow

(in millions)

2026 – Three Months Ended March 31,(1)2026 – Year Ended March 31,2025 – Year Ended March 31,Change
GAAP CASH FLOW CATEGORIESNet cash provided by operating activities3,4216,1556,0851
GAAP CASH FLOW CATEGORIESNet cash provided by (used in) investing activities425-3,432-733368
GAAP CASH FLOW CATEGORIESNet cash used in financing activities-2,820-4,631-3,96517
GAAP CASH FLOW CATEGORIESEffect of exchange rate changes on cash, cash equivalents, and restricted cash-1120-16225
GAAP CASH FLOW CATEGORIESNet increase (decrease) in cash, cash equivalents, and restricted cash1,015-1,8881,371-238
FREE CASH FLOW (NON-GAAP)Net cash provided by operating activities3,4216,1556,0851
FREE CASH FLOW (NON-GAAP)Payments for property, plant, and equipment-111-436-537-19
FREE CASH FLOW (NON-GAAP)Capitalized software expenditures-74-309-322-4
FREE CASH FLOW (NON-GAAP)Free Cash Flow (Non-GAAP)3,2365,4105,2264
Full release

This earnings release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by their use of terminology such as “believes,” “expects,” “anticipates,” “may,” “will,” “should,” “seeks,” “approximately,” “intends,” “projects,” “plans,” “estimates,” “targets,” or the negative of these words or other comparable terminology. Any discussion of our intent to separate our Medical-Surgical Solutions segment into an independent company, other anticipated or completed transactions, including the anticipated closings thereof, or synergies expected therefrom, litigation outcomes, financial outlook, guidance, trends, strategy, plans, assumptions, expectations, commitments, and intentions may also include forward-looking statements. Forward-looking statements are not representations of historical or current facts or circumstances and they involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, or implied. Readers should not place undue reliance on forward-looking statements, such as financial performance forecasts, which speak only as of the date they are first made. Except to the extent required by federal securities laws, we undertake no obligation to publicly release the result of any revisions to any forward-looking statements to reflect events or circumstances after the date the statements are made, or to reflect the occurrence of unanticipated events. Although it is not possible to predict or identify all such risks and uncertainties, we encourage investors to read the risk factors described in our publicly available filings with the Securities and Exchange Commission and news releases.

These risk factors include, but are not limited to: our planned separation of Medical-Surgical Solutions is contingent upon the satisfaction of certain conditions, may not be completed on the currently contemplated terms or timeline, or at all, and, if completed, may not achieve the intended financial and strategic benefits; we experience costly and disruptive legal disputes and settlements, including regarding our role in distributing controlled substances such as opioids; we experience losses not covered by insurance or indemnification; we are subject to frequently changing, extensive, complex, and challenging healthcare and other laws and policies; we from time to time record significant charges from impairment to goodwill, intangibles, and other long-lived assets; we experience cybersecurity incidents that might significantly compromise our technology systems or might result in material data breaches; we experience significant problems with information systems or networks; the adoption and use of artificial intelligence in our business operations exposes us to risks and uncertainties; we may be unsuccessful in achieving our strategic growth objectives; we may be unsuccessful in our efforts to implement initiatives to reduce or optimize our costs; we might be unable to successfully complete or integrate acquisitions or other strategic transactions, especially in the timeframes noted; we may not receive anticipated benefits from acquisitions or other strategic transactions; we might be adversely impacted by delays or other difficulties with divestitures; we are impacted by customer purchase reductions, contract non-renewals, payment defaults, and bankruptcies; our contracts with government entities involve future funding, payment, and compliance risks; we might be harmed by changes in our relationships or contracts with suppliers; our use of third-party data is subject to risks and limitations that could impede the growth of our data services business; we might be unable to successfully recruit and retain qualified employees; we might be adversely impacted by healthcare reform such as changes in pricing and reimbursement models; we might be adversely impacted by competition and industry consolidation; we are adversely impacted by changes or disruptions in product supply and have difficulties in sourcing or selling products due to a variety of causes; we are adversely impacted as a result of our distribution of generic pharmaceuticals; we are adversely impacted by changes in the economic environments in which we operate; changes affecting capital and credit markets might impede access to credit, increase borrowing costs, and disrupt banking services for us and our customers and suppliers and might impair the financial soundness of our customers and suppliers; we might be adversely impacted by changes in tax legislation or challenges to our tax positions; and we might be adversely impacted by conditions and events outside of our control, such as widespread public health issues, natural disasters, and geopolitical factors.

About McKesson Corporation... (truncated)ces to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at

McKesson.com and read

Stories & Insights.

We routinely use our website, investors.mckesson.com, to post information that may be material to investors, such as business developments, earnings, and financial performance, as well as presentation materials and details for upcoming and past events.

Contacts:

Investors

Investors@McKesson.com

Media Relations

MediaRelations@McKesson.com

Schedule 1

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Mckesson earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.